Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 9;23(24):15602. doi: 10.3390/ijms232415602

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effects of various treatment times with 0.5 μM SP600125 on PC12-P1F1 neuritogenesis while undergoing TRTS exposure. (a) Schematic representation of the treatment times of PC12-P1F1 cells with SP600125 in the presence of TRTS. PC12-P1F1 cells were stimulated with SP600125 under TRTS exposure as follows: all 7 days (TRTS + SP-A7), first 3 days (TRTS + SP-F3), and last 4 days (TRTS + SP-L4). (b) Phase-contrast images of PC12-P1F1 cells on day 7. Scale bars: 100 μm. (c) Percentage of neurite-bearing cells on day 7. Cells that did not undergo TRTS or SP600125 treatment were defined as the negative control group. The data represent the means ± standard deviation of three replicates. ^## p < 0.01; n.s., not significant; ^†† p < 0.01 vs. control; ** p < 0.01 vs. TRTS alone.